Acute leukemia: Mechanisms of cell survival as targets for therapy (review)

International Journal of Oncology

Volumn 11, Issue 4, 1997, Pages 657-674

  Karp, Judith E ^a  

^a UNIVERSITY OF MARYLAND MEDICAL SYSTEM   (United States)

Author keywords

Apoptosis; Cell cycle; DNA repair; Drug resistance; Leukemia

Indexed keywords

BETA INTERFERON; CYCLINE; PROTEIN P53;

ACUTE LEUKEMIA; APOPTOSIS; CELL DEATH; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; DNA DAMAGE; ENZYME ACTIVITY; HEMATOPOIESIS; HUMAN; HUMAN CELL; LEUKEMOGENESIS; MALIGNANT TRANSFORMATION; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

EID: 0030885291     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (23)

1. Burke PJ, Karp JE, Geller RB and Vaughan WP: Cures of leukemia with aggressive postremission treatment: an update of timed sequential therapy (Ac-D-Ac). Leukemia 3: 692-694, 1989.
2. Hoelzer D, Ludwig W-D, Thiel E, Gassman W, Loffler H, Fonatsch C, Rieder H, Heil G, Heinze B, Arnold R, Hossfeld D, Buchner T, Koch P, Freund M, Hiddemann W, Maschmeyer G, Heyll A, Aul C, Faak T, Kuse R, Ittel TH, Gramatzki M, Diedrich H, Kolbe K, Fuhr H-G, Fischer K, Schadeck-Gressel C, Weiss A, Strohscheer I, Metzner B, Fabry U, Gokbuget N, Volkers B, Messerer D and Uberla K: Improved outcome in adult B-cell acute lymphoblastic leukemia. Blood 87: 495-508, 1996.
3. Larson RA, Dodge RK, Burns CP, Lee EJ, Stone RM, Schulman P, Duggan D, Davey FR, Sobol RE, Frankel SR, Hooberman AL, Westbrook CA, Arthur DC, George SL, Bloomfield CD and Schiffer CA: A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811. Blood 85: 2025-2037, 1995.
4. Mayer RJ, Davis RB, Schiffer CA, Berg DT, Powell BL, Schulman P, Omura GA, Moore JO, McIntyre OR and Frei E III for the Cancer and Leukemia Group B: Intensive post-remission chemotherapy in adults with acute myeloid leukemia. N Engl J Med 331: 896-903, 1994.
5. Mitus AJ, Miller KB, Schenkein DP, Ryan HF, Parsons SK, Wheeler C and Antin JH: Improved survival for patients with acute myelogenous leukemia. J Clin Oncol 13: 560-569, 1995.
6. Karp JE and Smith MA: The molecular pathogenesis of treatment-induced (secondary) leukemias: foundations for treatment and prevention. Semin Oncol 24: 103-113, 1997.
7. Levine E and Bloomfield C: Leukemias and myelodysplastic syndromes secondary to drug, radiation and environmental exposure. Semin Oncol 19: 47-84, 1992.
8. Bhalla K, Ibrado AM, Tourkina E, Tang C, Grant S, Bullock G, Huang Y, Ponnathpur V and Mahoney ME: High-dose mitoxantrone induces programmed cell death or apoptosis in human myeloid leukemia cells. Blood 82: 3133-3140, 1993.
9. Datta R, Banach D, Kojima H, Talanian RV, Alnemri ES, Wong WW and Kufe DW: Activation of the CPP32 protease in apoptosis induced by 1-b-d-arabinofuranosylcytosine and other DNA-damaging agents. Blood 88: 1936-1943, 1996.
10. Lowe S, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, Housman DE and Jacks T: p53 status and the efficacy of cancer therapy in vivo. Science 266: 807-810, 1994.
11. Sachs L and Lotem J: Control of programmed cell death in normal and leukemic cells: new implications for therapy. Blood 82: 15-21, 1993.
12. Campos L, Rouault J-P, Sabido O, Oriol P, Roubi N, Vasselon C, Archimbaud E, Magaud J-P and Guyotat D: High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood 81: 3091-3096, 1993.
13. Goker E, Waltham M, Kheradpour A, Trippett T, Mazumdar M, Elisseyeff Y, Schnieders B, Steinherz P, Tan C, Berman E and Bertino JR: Amplification of the dihyrofolate reductase gene is a mechanism of acquired resistance to methotrexate in patients with acute lymphoblastic leukemia and is correlated with p53 mutations. Blood 86: 677-684, 1995.
14. Wattel E, Preudhomme C, Hecquet B, Vanrumbeke M, Quesnel B, Dervite I, Morel P and Fenaux P: p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood 84: 3148-3157, 1994.
15. Nurse P: Universal control mechanism regulating onset of M-phase. Nature 344: 503-508, 1990.
16. cdc2: the S and M kinase. New Biol 2: 389-401, 1990.
17. Reznitzky D, Gossen M, Bujard H and Reed SI: Acceleration of the G1/S phase transition by expression of cyclins D1 and E with an inducible system. Mol Cell Biol 14: 1669-1679, 1994.
18. Sherr CJ: Cancer cell cycles. Science 274: 1672-1677, 1996.
19. El-Deiry WS, Tokino T, Velcuiescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW and Vogelstein B: WAF1, a potential mediator of p53 tumor suppression. Cell 75: 817-825, 1993.
20. Harper JW, Adami GR, Wei N, Keyomarsi K and Elledge SJ: The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinascs. Cell 75: 805-816, 1993.
21. Dulic V, Kaufmann WK, Wilson SJ, Tisty TD, Lees E, Harper JW, Elledge SJ and Reed SI: p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell 76: 1013-1023, 1994.
22. Slebos RJC, Lee MH, Plunkett BS, Kessis TD, Williams BO, Jacks T, Hedrick L, Kastan MB and Cho KR: p53-dependent G1 arrest involves pRB-related proteins and is disrupted by the human papillomavirus 16 E7 oncoprotein. Proc Natl Acad Sci USA 91: 5320-5324, 1994.
23. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R and Beach D: p21 is a universal inhibitor of cyclin kinases. Nature 366: 701-738, 1993.